Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability


Excerpt

I Peace is expanding its proprietary clinical-grade induced pluripotent stem cell (iPSC) banking service – first by improving accessibility across Japan through a collaboration with I’rom Group, and then expanding to global markets including the U.S. Leveraging an increased mass manufacturing capability and reduced costs with the development of a novel system, the company expects to increase the number of available clinical-grade iPSC lines to a few thousand per year by 2025.

Article

Biotech start-up I Peace is expanding the personalised induced pluripotent stem cell (iPSC) banking service it launched in Japan in 2020. It will collaborate with I’rom Group Co., Ltd. (Japan), leveraging its vast network of 2245 hospitals and clinics, to improve the accessibility of the service all across the country, and subsequently launch the service in the U.S.

A pioneer in developing technology for mass manufacturing iPSCs in a closed system, I Peace developed an innovative new system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette in March 2020. With the modular and scalable technology, and its small footprint, the company intends to produce up to a few thousand lines of clinical-grade iPSCs in a year by 2025.

Apart from providing the company with a steady business flow, the expansion of the service benefits the cell therapy industry by helping identify diverse cell characteristics that could in turn aid therapy development and drug screening. Beyond its APAC-focused partnership with I’rom Group, I Peace is planning to apply this business model to facilitate a global expansion for the iPSC banking service.

About I’rom Group

The I’rom Group has four business units that together ensure that pharmaceuticals and medical technologies are accessible to patients that require them, through collaborations with medical institutions across the country and supporting clinical trials, as well as through research and development of advanced medicine and regenerative medicine, and sales of iPSC manufacturing tools. 

The Group has consistently been involved in all of these businesses and is committed to contributing to medical development, to elevate the quality of patients’ lives.

About I Peace, Inc.

Palo Alto-based I Peace focuses on the Nobel Prize-winning technology of iPSCs through its proprietary manufacturing platform which enables the fully automated mass production of discrete iPSCs from multiple donors in a single room. This aids customers in selecting the most appropriate iPSC line for their clinical research at a reduced cost, with the ultimate goal of providing every individual a source of their own personalised stem cells through the creation of iPSCs. For more information, visit https://www.ipeace.com .

About Founder and CEO Dr. Koji Tanabe

While obtaining his Ph.D. from Kyoto University Graduate School of Medicine and working in the laboratory of 2012 Nobel Prize Winner Professor Shinya Yamanaka, Dr. Koi Tanabe became the second author of the scientific paper reporting the world’s first successful generation of human iPSCs. He then moved to the U.S. and joined the Dr. Marius Wernig Laboratory at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University Medical School, where his work focused on direct reprogramming of blood cells to neural cells and the iPSC reprogramming mechanism. Dr. Tanabe became CEO at I Peace after spending time as a guest researcher at Stanford, and has been awarded an Overseas Research Fellowship by the Japan Society for the Promotion of Science.

(Source: Cision, 7th September 2021)


Excerpt

I Peace is expanding its proprietary clinical-grade induced pluripotent stem cell (iPSC) banking service – first by improving accessibility across Japan through a collaboration with I’rom Group, and then expanding to global markets including the U.S. Leveraging an increased mass manufacturing capability and reduced costs with the development of a novel system, the company expects to increase the number of available clinical-grade iPSC lines to a few thousand per year by 2025.

Article

Biotech start-up I Peace is expanding the personalised induced pluripotent stem cell (iPSC) banking service it launched in Japan in 2020. It will collaborate with I’rom Group Co., Ltd. (Japan), leveraging its vast network of 2245 hospitals and clinics, to improve the accessibility of the service all across the country, and subsequently launch the service in the U.S.

A pioneer in developing technology for mass manufacturing iPSCs in a closed system, I Peace developed an innovative new system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette in March 2020. With the modular and scalable technology, and its small footprint, the company intends to produce up to a few thousand lines of clinical-grade iPSCs in a year by 2025.

Apart from providing the company with a steady business flow, the expansion of the service benefits the cell therapy industry by helping identify diverse cell characteristics that could in turn aid therapy development and drug screening. Beyond its APAC-focused partnership with I’rom Group, I Peace is planning to apply this business model to facilitate a global expansion for the iPSC banking service.

About I’rom Group

The I’rom Group has four business units that together ensure that pharmaceuticals and medical technologies are accessible to patients that require them, through collaborations with medical institutions across the country and supporting clinical trials, as well as through research and development of advanced medicine and regenerative medicine, and sales of iPSC manufacturing tools. 

The Group has consistently been involved in all of these businesses and is committed to contributing to medical development, to elevate the quality of patients’ lives.

About I Peace, Inc.

Palo Alto-based I Peace focuses on the Nobel Prize-winning technology of iPSCs through its proprietary manufacturing platform which enables the fully automated mass production of discrete iPSCs from multiple donors in a single room. This aids customers in selecting the most appropriate iPSC line for their clinical research at a reduced cost, with the ultimate goal of providing every individual a source of their own personalised stem cells through the creation of iPSCs. For more information, visit https://www.ipeace.com .

About Founder and CEO Dr. Koji Tanabe

While obtaining his Ph.D. from Kyoto University Graduate School of Medicine and working in the laboratory of 2012 Nobel Prize Winner Professor Shinya Yamanaka, Dr. Koi Tanabe became the second author of the scientific paper reporting the world’s first successful generation of human iPSCs. He then moved to the U.S. and joined the Dr. Marius Wernig Laboratory at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University Medical School, where his work focused on direct reprogramming of blood cells to neural cells and the iPSC reprogramming mechanism. Dr. Tanabe became CEO at I Peace after spending time as a guest researcher at Stanford, and has been awarded an Overseas Research Fellowship by the Japan Society for the Promotion of Science.

(Source: Cision, 7th September 2021)


Excerpt

I Peace is expanding its proprietary clinical-grade induced pluripotent stem cell (iPSC) banking service – first by improving accessibility across Japan through a collaboration with I’rom Group, and then expanding to global markets including the U.S. Leveraging an increased mass manufacturing capability and reduced costs with the development of a novel system, the company expects to increase the number of available clinical-grade iPSC lines to a few thousand per year by 2025.

Article

Biotech start-up I Peace is expanding the personalised induced pluripotent stem cell (iPSC) banking service it launched in Japan in 2020. It will collaborate with I’rom Group Co., Ltd. (Japan), leveraging its vast network of 2245 hospitals and clinics, to improve the accessibility of the service all across the country, and subsequently launch the service in the U.S.

A pioneer in developing technology for mass manufacturing iPSCs in a closed system, I Peace developed an innovative new system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette in March 2020. With the modular and scalable technology, and its small footprint, the company intends to produce up to a few thousand lines of clinical-grade iPSCs in a year by 2025.

Apart from providing the company with a steady business flow, the expansion of the service benefits the cell therapy industry by helping identify diverse cell characteristics that could in turn aid therapy development and drug screening. Beyond its APAC-focused partnership with I’rom Group, I Peace is planning to apply this business model to facilitate a global expansion for the iPSC banking service.

About I’rom Group

The I’rom Group has four business units that together ensure that pharmaceuticals and medical technologies are accessible to patients that require them, through collaborations with medical institutions across the country and supporting clinical trials, as well as through research and development of advanced medicine and regenerative medicine, and sales of iPSC manufacturing tools. 

The Group has consistently been involved in all of these businesses and is committed to contributing to medical development, to elevate the quality of patients’ lives.

About I Peace, Inc.

Palo Alto-based I Peace focuses on the Nobel Prize-winning technology of iPSCs through its proprietary manufacturing platform which enables the fully automated mass production of discrete iPSCs from multiple donors in a single room. This aids customers in selecting the most appropriate iPSC line for their clinical research at a reduced cost, with the ultimate goal of providing every individual a source of their own personalised stem cells through the creation of iPSCs. For more information, visit https://www.ipeace.com .

About Founder and CEO Dr. Koji Tanabe

While obtaining his Ph.D. from Kyoto University Graduate School of Medicine and working in the laboratory of 2012 Nobel Prize Winner Professor Shinya Yamanaka, Dr. Koi Tanabe became the second author of the scientific paper reporting the world’s first successful generation of human iPSCs. He then moved to the U.S. and joined the Dr. Marius Wernig Laboratory at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University Medical School, where his work focused on direct reprogramming of blood cells to neural cells and the iPSC reprogramming mechanism. Dr. Tanabe became CEO at I Peace after spending time as a guest researcher at Stanford, and has been awarded an Overseas Research Fellowship by the Japan Society for the Promotion of Science.

(Source: Cision, 7th September 2021)


Excerpt

I Peace is expanding its proprietary clinical-grade induced pluripotent stem cell (iPSC) banking service – first by improving accessibility across Japan through a collaboration with I’rom Group, and then expanding to global markets including the U.S. Leveraging an increased mass manufacturing capability and reduced costs with the development of a novel system, the company expects to increase the number of available clinical-grade iPSC lines to a few thousand per year by 2025.

Article

Biotech start-up I Peace is expanding the personalised induced pluripotent stem cell (iPSC) banking service it launched in Japan in 2020. It will collaborate with I’rom Group Co., Ltd. (Japan), leveraging its vast network of 2245 hospitals and clinics, to improve the accessibility of the service all across the country, and subsequently launch the service in the U.S.

A pioneer in developing technology for mass manufacturing iPSCs in a closed system, I Peace developed an innovative new system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette in March 2020. With the modular and scalable technology, and its small footprint, the company intends to produce up to a few thousand lines of clinical-grade iPSCs in a year by 2025.

Apart from providing the company with a steady business flow, the expansion of the service benefits the cell therapy industry by helping identify diverse cell characteristics that could in turn aid therapy development and drug screening. Beyond its APAC-focused partnership with I’rom Group, I Peace is planning to apply this business model to facilitate a global expansion for the iPSC banking service.

About I’rom Group

The I’rom Group has four business units that together ensure that pharmaceuticals and medical technologies are accessible to patients that require them, through collaborations with medical institutions across the country and supporting clinical trials, as well as through research and development of advanced medicine and regenerative medicine, and sales of iPSC manufacturing tools. 

The Group has consistently been involved in all of these businesses and is committed to contributing to medical development, to elevate the quality of patients’ lives.

About I Peace, Inc.

Palo Alto-based I Peace focuses on the Nobel Prize-winning technology of iPSCs through its proprietary manufacturing platform which enables the fully automated mass production of discrete iPSCs from multiple donors in a single room. This aids customers in selecting the most appropriate iPSC line for their clinical research at a reduced cost, with the ultimate goal of providing every individual a source of their own personalised stem cells through the creation of iPSCs. For more information, visit https://www.ipeace.com .

About Founder and CEO Dr. Koji Tanabe

While obtaining his Ph.D. from Kyoto University Graduate School of Medicine and working in the laboratory of 2012 Nobel Prize Winner Professor Shinya Yamanaka, Dr. Koi Tanabe became the second author of the scientific paper reporting the world’s first successful generation of human iPSCs. He then moved to the U.S. and joined the Dr. Marius Wernig Laboratory at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University Medical School, where his work focused on direct reprogramming of blood cells to neural cells and the iPSC reprogramming mechanism. Dr. Tanabe became CEO at I Peace after spending time as a guest researcher at Stanford, and has been awarded an Overseas Research Fellowship by the Japan Society for the Promotion of Science.

(Source: Cision, 7th September 2021)


Excerpt

I Peace is expanding its proprietary clinical-grade induced pluripotent stem cell (iPSC) banking service – first by improving accessibility across Japan through a collaboration with I’rom Group, and then expanding to global markets including the U.S. Leveraging an increased mass manufacturing capability and reduced costs with the development of a novel system, the company expects to increase the number of available clinical-grade iPSC lines to a few thousand per year by 2025.

Article

Biotech start-up I Peace is expanding the personalised induced pluripotent stem cell (iPSC) banking service it launched in Japan in 2020. It will collaborate with I’rom Group Co., Ltd. (Japan), leveraging its vast network of 2245 hospitals and clinics, to improve the accessibility of the service all across the country, and subsequently launch the service in the U.S.

A pioneer in developing technology for mass manufacturing iPSCs in a closed system, I Peace developed an innovative new system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette in March 2020. With the modular and scalable technology, and its small footprint, the company intends to produce up to a few thousand lines of clinical-grade iPSCs in a year by 2025.

Apart from providing the company with a steady business flow, the expansion of the service benefits the cell therapy industry by helping identify diverse cell characteristics that could in turn aid therapy development and drug screening. Beyond its APAC-focused partnership with I’rom Group, I Peace is planning to apply this business model to facilitate a global expansion for the iPSC banking service.

About I’rom Group

The I’rom Group has four business units that together ensure that pharmaceuticals and medical technologies are accessible to patients that require them, through collaborations with medical institutions across the country and supporting clinical trials, as well as through research and development of advanced medicine and regenerative medicine, and sales of iPSC manufacturing tools. 

The Group has consistently been involved in all of these businesses and is committed to contributing to medical development, to elevate the quality of patients’ lives.

About I Peace, Inc.

Palo Alto-based I Peace focuses on the Nobel Prize-winning technology of iPSCs through its proprietary manufacturing platform which enables the fully automated mass production of discrete iPSCs from multiple donors in a single room. This aids customers in selecting the most appropriate iPSC line for their clinical research at a reduced cost, with the ultimate goal of providing every individual a source of their own personalised stem cells through the creation of iPSCs. For more information, visit https://www.ipeace.com .

About Founder and CEO Dr. Koji Tanabe

While obtaining his Ph.D. from Kyoto University Graduate School of Medicine and working in the laboratory of 2012 Nobel Prize Winner Professor Shinya Yamanaka, Dr. Koi Tanabe became the second author of the scientific paper reporting the world’s first successful generation of human iPSCs. He then moved to the U.S. and joined the Dr. Marius Wernig Laboratory at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University Medical School, where his work focused on direct reprogramming of blood cells to neural cells and the iPSC reprogramming mechanism. Dr. Tanabe became CEO at I Peace after spending time as a guest researcher at Stanford, and has been awarded an Overseas Research Fellowship by the Japan Society for the Promotion of Science.

(Source: Cision, 7th September 2021)

Comments

Leave A Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

bag